Revance expects 2023 GAAP operating expenses to be $460 million to $480 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization and stock-based compensation to be $320 million to $340 million. Revance expects 2023 non-GAAP research and development expenses to be $80 million to $90 million. The company’s non-GAAP operating expense guidance for 2023 primarily reflects increased investments in its aesthetics commercial infrastructure, including sales team expansion, DAXXIFY(R) and RHA(R) Collection commercial investment, and biosimilar partnership investment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVNC:
- 3 Best Stocks to Buy Now, 8/9/2023, According to Top Analysts
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Revance Therapeutics (RVNC) Q2 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 7/31/2023, According to Top Analysts